Pfizer and BioNTech have applied to US regulatory authorities for emergency authorisation of a Covid-19 vaccine specifically tailored to target the most dominant strain of the Omicron variant ahead of a nationwide booster programme planned for the autumn.
The companies said on Monday they had rapidly increased production of the newly developed shot targeting the fast spreading BA.4/BA.5 sub-variants and stand ready to deliver doses from September.
Shipping could begin immediately if regulators authorised the new “bivalent” vaccine, which contains the original Covid strain and the genetic code for the now dominant sub-variants, they added.
您已閱讀24%（649字），剩余76%（2048字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。